On April 7, 2026, the U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), launched the READI-Home (Reducing Readmissions through Device Innovation in the Home) Innovation Challenge as part of its broader "Home as a Health Care Hub" initiative. The program is designed to accelerate the development of medical devices that enable safe, effective care in the home and reduce avoidable hospital readmissions.
Hospital readmissions are a significant cost and quality challenge, particularly for those with multiple chronic conditions. An aging population, a rising chronic disease burden, provider shortages, and increasing healthcare costs are driving a shift toward decentralized, patient-centered care models.
The FDA's initiative is designed for a strategic pivot to position the home as a core site of care delivery, supported by connected, user-friendly medical technologies. The READI-Home challenge seeks to:
- Identify and accelerate innovative medical devices that support recovery after hospital discharge
- Reduce preventable readmissions by improving monitoring, adherence, and early intervention in the home
- Empower patients and caregivers with technologies designed for non-clinical settings and
- Advance health equity by enabling access to care outside traditional healthcare facilities
The initiative prioritizes solutions that address unmet clinical needs and are usable by patients or lay caregivers in real-world home environments. The challenge is structured in two phases:
- Submission and Selection Phase (April - September 2026). Applicants submit proposals through the FDA's Q-submission process. Submissions must include device descriptions, feasibility evidence, and a data development plan
- FDA Collaboration ("Sprint") Phase (Beginning December 2026). Up to nine selected participants engage in intensive collaboration with FDA experts. Participants receive iterative feedback on device design, testing, and regulatory strategy
According to the FDA, the READI-Home challenge offers early and frequent interaction with FDA reviewers.
Note: Participation does not constitute premarket approval but is intended to streamline future regulatory review.
Additionally, the READI-Home challenge builds on the FDA's broader "Home as a Health Care Hub" framework, which is intended to reimagine the home as an integrated extension of the healthcare system. This includes efforts to design interoperable, patient-centered device ecosystems and to address barriers such as usability, access, and data integration.
With this challenge, the FDA is signaling strong support for home-based medical device innovation as a tool to reduce costs and improve outcomes. The READI-Home Innovation Challenge represents a targeted FDA effort to catalyze next-generation medical devices that shift care into the home. By combining regulatory engagement with innovation incentives, the program is intended to reduce hospital readmissions while advancing a more decentralized, patient-centric healthcare system.
Interested device innovators can achieve early engagement with FDA through structured programs like READI-Home that may provide a strategic regulatory advantage. Companies developing remote monitoring, AI-enabled diagnostics, or caregiver-operated devices may find significant opportunities in this space. Solutions that demonstrate clear impact on readmissions and usability in non-clinical settings will be best positioned for selection.
As with any product going through FDA approval, it is important to contemporaneously develop a commercial launch plan that includes a coverage and reimbursement strategy for Medicare, Medicaid, and commercial insurance. The Venable team can provide guidance to companies, from concept inception through FDA approval and payor coverage.
Please let us know if you would like further information and or assistance with this new FDA initiative. Venable's FDA, Healthcare and Healthcare Policy teams are ready to provide support and counsel when you need it.
